Loading…
TransMedics Group, Inc. is projected to rise to $85.68 by 2027, a +22% move from its current price of $70.15. TMDX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $67.90 | $70.13 | $72.43 | -0.03% |
| May 30 | $66.97 | $70.10 | $73.38 | -0.07% |
| May 31 | $66.26 | $70.08 | $74.11 | -0.10% |
| Jun 1 | $65.67 | $70.06 | $74.73 | -0.14% |
| Jun 2 | $65.15 | $70.03 | $75.28 | -0.17% |
| Jun 3 | $64.68 | $70.01 | $75.77 | -0.20% |
| Jun 4 | $64.25 | $69.98 | $76.23 | -0.24% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $64.25 | $69.98 | $76.23 | -0.24% |
| Week 2 | $61.87 | $69.82 | $78.79 | -0.47% |
| Week 3 | $60.07 | $69.65 | $80.77 | -0.71% |
| Week 4 | $58.57 | $69.49 | $82.45 | -0.94% |
| Week 5 | $57.26 | $69.32 | $83.93 | -1.18% |
| Week 6 | $56.09 | $69.16 | $85.27 | -1.41% |
| Week 7 | $55.03 | $69.00 | $86.51 | -1.64% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
TransMedics Group, Inc. is a commercial-stage healthcare technology company that focuses on transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that replicates near-physiologic conditions for donor organs outside of the human body.
Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart for preservation of donor hearts and for ex vivo reanimation and beating-heart preservation; and OCS Liver for the preservation of donor livers. TransMedics also developed a national OCS program and offers OCS organ management and logistics services, including aviation and ground transportation. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
TransMedics Group, Inc. trades under the ticker TMDX and operates in the Healthcare sector. The stock is currently priced at $68.94 with a market capitalization of $2.38B and a market-rank of 1889. The current price sits within a longer-term forecast that envisions a bullish path ahead, with notable upside in the later years of the forecast window.
A major floor 59.1% below — a decisive break under it would weaken the trend.
The nearest floor, 11.6% below — buyers have tended to step in here.
The nearest ceiling, 65.5% above — a clean break opens room to run.
A major ceiling 111.0% above — clearing it would confirm fresh momentum.
Key TMDX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TMDX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $69.28 | Buy | $69.26 | Buy |
| MA 10 | $67.03 | Buy | $69.93 | Buy |
| MA 20 | $75.18 | Sell | $76.22 | Sell |
| MA 50 | $95.53 | Sell | $92.63 | Sell |
| MA 100 | $115.46 | Sell | $105.52 | Sell |
| MA 200 | $119.03 | Sell | $111.95 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 34.17 | Neutral |
| Stoch RSI (14) | 98.21 | Sell |
| CCI (20) | -29.02 | Neutral |
| Williams %R (14) | -25.32 | Info |
| MACD (12,26,9) | 1.32 | Buy |
| ROC (12) | 3.41 | Buy |
| Bollinger %B (20,2) | 0.41 | Neutral |
| Stochastic %K (14) | 74.68 | Neutral |
| TRIX (15) | -1.67 | Sell |
| Awesome (5,34) | -20.93 | Sell |
| Ultimate (7,14,28) | 61.86 | Neutral |
| Momentum (10) | 6.22 | Buy |
| Aroon Osc (25) | -64.00 | Sell |
| Hull MA (9) | 70.83 | Sell |
| ADX (14) | 37.31 | Sell |
| ATR (14) | 2.60 | Info |
Near term, the technical picture is mixed but leaning cautious. The RSI(14) is 30, indicating neutral to oversold conditions. The 50-day simple moving average sits at $97.68, while the 200-day simple moving average is at $119.48, suggesting the stock is trading below both major averages.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $62.04 | $70.15 | $90.81 | 0% | Neutral | |
| $66.74 | $85.68 | $117.21 | +22% | Bullish | |
| $69.53 | $92.23 | $131.46 | +31% | Bullish | |
| $72.18 | $98.43 | $144.91 | +40% | Bullish | |
| $76.24 | $106.54 | $161.20 | +52% | Bullish | |
| $66.59 | $95.18 | $147.48 | +36% | Bullish | |
| $67.19 | $98.10 | $155.28 | +40% | Bullish | |
| $74.20 | $110.51 | $178.35 | +58% | Bullish | |
| $78.62 | $119.35 | $196.06 | +70% | Bullish | |
| $91.67 | $141.73 | $236.69 | +102% | Bullish | |
| $89.72 | $150.85 | $269.90 | +115% | Bullish | |
| $164.12 | $320.11 | $632.75 | +356% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $62.04 | $70.15 | $82.77 | +0.00% |
| June 2026 | $60.02 | $70.77 | $85.64 | +0.89% |
| July 2026 | $57.11 | $68.02 | $83.62 | -3.89% |
| August 2026 | $56.25 | $67.51 | $84.01 | -0.74% |
| September 2026 | $58.33 | $70.48 | $88.56 | +4.39% |
| October 2026 | $58.34 | $70.90 | $89.89 | +0.60% |
| November 2026 | $56.57 | $69.12 | $88.32 | -2.51% |
| December 2026 | $57.46 | $70.55 | $90.81 | +2.07% |
Click any year to see its month-by-month TMDX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
TransMedics Group, Inc.'s 2026 outlook centres on $70.15, within a $62.04 to $90.81 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, TMDX could reach as high as $117.21, with a base case around $85.68 and support toward $66.74 — roughly +22% from $70.15. Buyers look set to stay in control over this stretch.
Expect TMDX to range from $69.53 to $131.46 through 2028. The $92.23 average target implies a +31% move from current prices. That is up +8% on the projected 2027 average. Momentum favours further upside here.
The TMDX price prediction for 2029 points to an average of $98.43 (low $72.18, high $144.91) — a potential gain of +40% on today's $70.15. Buyers look set to stay in control over this stretch.
In 2030, TMDX is projected to trade between $76.24 and $161.20, averaging $106.54 — a potential gain of +52% from today's $70.15. That is up +8% on the projected 2029 average. Momentum favours further upside here.
TransMedics Group, Inc.'s 2031 outlook centres on $95.18, within a $66.59 to $147.48 range. That is -11% versus the projected 2030 average. That marks a +36% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, TMDX could reach as high as $155.28, with a base case around $98.10 and support toward $67.19 — roughly +40% from $70.15. Momentum favours further upside here.
Expect TMDX to range from $74.20 to $178.35 through 2033. The $110.51 average target implies a +58% move from current prices. That is up +13% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The TMDX price prediction for 2034 points to an average of $119.35 (low $78.62, high $196.06) — a potential gain of +70% on today's $70.15. Momentum favours further upside here.
In 2035, TMDX is projected to trade between $91.67 and $236.69, averaging $141.73 — a potential gain of +102% from today's $70.15. That is up +19% on the projected 2034 average. Buyers look set to stay in control over this stretch.
TransMedics Group, Inc.'s 2040 outlook centres on $150.85, within a $89.72 to $269.90 range. That is up +6% on the projected 2035 average. That marks a +115% change versus current levels. Momentum favours further upside here.
By 2050, TMDX could reach as high as $632.75, with a base case around $320.11 and support toward $164.12 — roughly +356% from $70.15. Buyers look set to stay in control over this stretch.
Investing $1,000 in TMDX today (≈ 14.255167 TMDX) could be worth
$4,563.21
+$3,563.21 (+356%) by 2050 · US Dollar
Based on the average projected TMDX price of $320.11 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TMDXwould be worth at today's price.
$1,000 invested in TMDX on May 27, 2025 (≈ 7.780285 TMDX) would be worth
$545.79
-$454.21 (-45.4%) today · 0.55× · US Dollar
Based on a TMDX entry price of $128.53 vs. today's $70.15.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $68 | $1,031.62 | +3.2% |
| 1 month ago | $108.12 | $648.82 | -35.1% |
| 3 months ago | $134.57 | $521.29 | -47.9% |
| 6 months ago | $146.31 | $479.46 | -52.1% |
| 1 year ago | $128.53 | $545.79 | -45.4% |
| All time (5.0y) ago | $25.92 | $2,706.4 | +170.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TMDX forecast.
Our base-case forecast reaches $140.00 around 2035.
Implied market cap at $140.00: $4.84B
The multi-year forecast shows a bullish trajectory after 2026. In 2026 the average price is $68.94 with a min of $62.04 and a max of $90.19, and ROI is 0. By 2027 the average rises to $84.09 (min $65.06, max $116.05, ROI 22) and remains bullish through 2030, with an average of $104.73 and a max of $160.49, ROI 51.9.
The sequence continues with 2031–2032 averages near $92.60–$96.28 and rising confidence, and 2033–2035 showing stronger gains (2033 avg $108.04, max $177.01; 2034 avg $116.33, max $194.14; 2035 avg $139.88, max $237.47; ROI 56.7, 68.8, and 102.9 respectively). By 2040 the average is $145.94 (max $266.04, ROI 111.7), and by 2050 the average reaches $314.69 (max $635.79, ROI 356.5). Sentiment shifts to bullish from 2027 onward, reflecting an expanding long-term growth outlook, but these are estimates and not guarantees of future results.
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $104.73, with a Min of $74.05 and a Max of $160.49, and a projected ROI of 51.9. The sentiment is bullish.
Forecasts show a bullish sentiment from 2027 onward with rising average prices and ROI, starting from an average of $84.09 in 2027 and increasing to $104.73 in 2030 and beyond. In 2026 the forecast is neutral, but these figures are estimates, not guarantees, and do not constitute financial advice.
Yes, the forecast maximum for 2035 is $237.47, and higher maximums appear in later years such as 2040 ($266.04) and 2050 ($635.79). The 2035 max is $237.47.
Current price is $68.94 and market capitalization is $2.38B.
Near term, the RSI(14) is 30 (neutral). The 50-day SMA is $97.68 and the 200-day SMA is $119.48. Support is at $62.04 and resistance at $116.11, with the 30-day price range between $55.08 and $86.27 and annualized volatility around 70%.
TransMedics Group, Inc. Community Discussion
0Share your TransMedics Group, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.